FrancophonIA/ELRC3.0 huggingface dataset:
English: Pramipexole stimulates the brain as dopamine would, so that patients can control their movement and have fewer of the signs and symptoms of Parkinson's disease, such as shaking, stiffness and slowness of movement.
Estonian: Pramipeksool stimuleerib aju samamoodi kui dopamiin, et patsiendid saaksid juhtida liigutusi ning et neil väheneksid Parkinsoni tõve nähud ja sümptomid, näiteks värin, jäikus ja liigutuste aeglus.
English: This means that Pramipexole Teva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Sifrol.
Estonian: See tähendab, et Pramipexole Teva on sarnane võrdlusravimiga Sifrol, millel juba on Euroopa Liidus müügiluba.
English: Because Pramipexole Teva is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine (i.e. that the two medicines produce the same levels of the active substance in the body).
Estonian: Et Pramipexole Teva on geneeriline ravim, piirdusid uuringud katsetega, milles näidati Pramipexole Teva bioekvivalentsust võrdlusravimiga (st need kaks ravimit tekitavad organismis toimeainet samal määral).
English: Because Pramipexole Teva is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Estonian: Et Pramipexole Teva on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: Pramipexole Teva is a ‘generic medicine'.
Estonian: Pramipexole Teva on geneeriline ravim.
English: Pramipexole Teva is a medicine containing the active substance pramipexole base.
Estonian: Pramipexole Teva on ravim, mis sisaldab toimeainena pramipeksooli alust.
English: What are the benefit and risk of Pramipexole Teva?
Estonian: Mis on Pramipexole Teva kasulikkus ja riskid?
English: The full EPAR for Pramipexole Teva can be found here.
Estonian: Euroopa avaliku hindamisaruande täisteksti Pramipexole Teva kohta leiate siit.
English: Other information about Pramipexole Teva:
Estonian: Muu teave Pramipexole Teva kohta
English: Pramipexole Teva must be given less frequently in patients who have problems with their kidneys.
Estonian: Neeruprobleemidega patsientidele tuleb Pramipexole Tevat manustada harvemini.
English: What is Pramipexole Teva?
Estonian: Mis on Pramipexole Teva?
English: The active substance in Pramipexole Teva, pramipexole, is a dopamine agonist, which imitates the action of dopamine.
Estonian: Pramipexole Teva toimeaine pramipeksool on dopamiini agonist ja selle toime on samasugune kui dopamiinil.
English: Why has Pramipexole Teva been approved?
Estonian: Miks Pramipexole Teva heaks kiideti?
English: Pramipexole Teva is used to treat the symptoms of Parkinson's disease, a progressive brain disorder that causes shaking, slow movement and muscle stiffness.
Estonian: Parkinsoni tõbi on progresseeruv ajuhäire, mis põhjustab värinat, liigutuste aeglust ja lihasjäikust.
English: How has Pramipexole Teva been studied?
Estonian: Kuidas Pramipexole Tevat uuriti?
English: How is Pramipexole Teva used?
Estonian: Kuidas Pramipexole Tevat kasutatakse?
English: What is Pramipexole Teva used for?
Estonian: Milleks Pramipexole Tevat kasutatakse?
English: The full EPAR for the reference medicine can also be found on the EMEA's website.
Estonian: Euroopa Ravimiameti veebilehel on avaldatud Euroopa avaliku hindamisaruande täistekst ka võrdlusravimi kohta.
English: How does Pramipexole Teva work?
Estonian: Kuidas Pramipexole Teva toimib?
English: 6 spare Insulin Release Units (IRUs)
Estonian: 6 insuliini vabastavat varuseadet (IRUt)
English: 1 insulin inhaler
Estonian: 1 insuliini inhalaator 1 varukamber
English: Invented name
Estonian: Manustamisviis
English: 1 spare chamber
Estonian: 270 x 1 blister (9 kotti)
English: Strength Pharmaceutical Form Route of Administration Packaging
Estonian: Ravimvorm
English: Efficib is taken twice a day.
Estonian: Efficibi võetakse kaks korda ööpäevas.
English: Other information about Efficib
Estonian: Muu teave Efficibi kohta
English: The European Commission granted a marketing authorisation valid throughout the EU for Efficib on 16 July 2008.
Estonian: Euroopa Komisjon andis Efficibi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 16. juulil 2008.
English: The full EPAR for Efficib can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Efficibi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The results of three further studies were used to support the use of Efficib.
Estonian: Efficibi kasutamise toetamiseks kasutati kolme muu uuringu tulemusi.
English: The most common side effect with Efficib (seen in between 1 and 10 patients in 100) is nausea (feeling sick).
Estonian: Efficibi kõige sagedam kõrvalnäht (esinenud 1-10 patsiendil 100st) on iiveldus.
English: The company also carried out additional studies to show that the active substances in Efficib are absorbed by the body in the same way as the two medicines given separately.
Estonian: Ettevõte tegi ka lisauuringud, et tõendada, et Efficibi toimeained imenduvad organismis samamoodi kui kumbki aine eraldi manustatuna.
English: The CHMP decided that Efficib's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Efficibi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: The company presented the results of three studies of Januvia/Xelevia to support the use of Efficib in patients who were not satisfactorily controlled on their existing metformin treatment.
Estonian: Ettevõte esitas Januvia/Xelevia kolme uuringu tulemused, et toetada Efficibi kasutamist patsientidel, kelle senine metformiiniravi ei andnud rahuldavaid tulemusi.
English: This is a summary of the European public assessment report (EPAR) for Efficib.
Estonian: See on ravimi Efficib Euroopa avaliku hindamisaruande kokkuvõte.
English: For more information about treatment with Efficib, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Efficibiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Efficib is a medicine that contains two active substances, sitagliptin and metformin hydrochloride.
Estonian: Efficib on ravim, mis sisaldab kaht toimeainet, sitagliptiini ja metformiinvesinikkloriidi.
English: Efficib sitagliptin / metformin hydrochloride
Estonian: Efficib sitagliptiin/metformiinvesinikkloriid
English: In the first of the three further studies, Efficib was more effective than metformin or sitagliptin alone.
Estonian: Kolmest lisauuringust esimeses oli Efficib efektiivsem kui ainult metformiin või sitagliptiin.
English: It must not be used in patients who have diabetic ketoacidosis or pre coma (dangerous conditions that can occur in diabetes), problems with the kidneys or liver, conditions that may affect the kidneys, or a disease that causes a reduced supply of oxygen to the tissues such as failure of the heart or lungs or a recent heart attack.
Estonian: Ravimit ei tohi kasutada ka patsiendid, kellel on diabeetiline ketoatsidoos või kooma eelseisund (diabeedi korral esineda võivad ohtlikud seisundid), neeru- või maksaprobleemid, neerukahjustuse riskiga seisundid või haigus, mis vähendab kudede hapnikuvarustust, näiteks südame- või kopsupuudulikkus või hiljutine südameinfarkt.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Efficib.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: If Efficib is taken with a sulphonylurea or insulin, the dose of the sulphonylurea or insulin may need to be lowered, to avoid hypoglycaemia (low blood sugar levels).
Estonian: Kui Efficibi võetakse koos sulfonüüluurearavimiga või insuliiniga, võib olla vaja vähendada sulfonüüluurearavimi või insuliini annust, et ennetada hüpoglükeemiat (normaalsest väiksem glükoosisisaldus veres).
English: Efficib was more effective than metformin alone.
Estonian: Efficib oli efektiivsem kui ainsa ravimina kasutatud metformiin.
English: For the full list of all side effects reported with Efficib, see the package leaflet.
Estonian: Efficibi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Efficib must not be used in people who are hypersensitive (allergic) to sitagliptin, metformin or any of the other ingredients.
Estonian: Efficibi ei tohi kasutada patsiendid, kes on sitagliptiini, metformiini või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: What is the risk associated with Efficib?
Estonian: Mis riskid Efficibiga kaasnevad?
English: The active substances in Efficib, sitagliptin and metformin hydrochloride, each have a different mode of action.
Estonian: Efficibi toimeained sitagliptiin ja metformiinvesinikkloriid on kumbki eri toimega.
English: What is Efficib?
Estonian: Mis on Efficib?
English: Why has Efficib been approved?
Estonian: Miks Efficib heaks kiideti?
English: The first included 1,091 patients who were not satisfactorily controlled on diet and exercise alone and compared the effect of Efficib with that of metformin or sitagliptin alone.
Estonian: Esimeses uuringus osales 1091 patsienti, kelle seisundit ei saanud rahuldavalt reguleerida üksnes dieedi ja füüsilise koormusega, ning selles võrreldi Efficibi toimet ainsa ravimina võetud metformiini või sitagliptiini toimega.
English: Efficib is used in patients with type 2 diabetes to improve the control of blood glucose (sugar) levels.
Estonian: Efficibi kasutatakse II tüüpi diabeediga (suhkurtõvega) patsientide raviks, et parandada vere glükoosisisalduse reguleeritavust organismis.
English: It must also not be used in patients who consume excessive amounts of alcohol or are alcoholic, or in women who are breast-feeding.
Estonian: Ravimit ei tohi kasutada ka alkoholi liigtarvitmise ega alkoholismi korral, samuti imetamise ajal.
English: What benefit has Efficib shown during the studies?
Estonian: Milles seisneb uuringute põhjal Efficibi kasulikkus?
English: How does Efficib work?
Estonian: Kuidas Efficib toimib?
English: How has Efficib been studied?
Estonian: Kuidas Efficibi uuriti?
English: What is Efficib used for?
Estonian: Milleks Efficibi kasutatakse?
English: The medicine can only be obtained with a prescription.
Estonian: Efficib on retseptiravim.
English: How is Efficib used?
Estonian: Kuidas Efficibi kasutatakse?
English: Efficib should be taken with food to avoid any stomach problems caused by metformin.
Estonian: Sitagliptiini suurim ööpäevane annus on 100 mg. Efficibi peab võtma koos söögiga, et ennetada metformiini tõttu tekkivaid maokahjustusi.
English: Octegra was initially approved in June 1999.
Estonian: Octegra sai algselt müügiloa 1999. aasta juunis.
English: 190 09 Pikermi- Attica- Athens Greece
Estonian: 190 09 Pikermi- Attica- Athens Kreeka
English: LU- Luxembourg Therabel Pharma 110 Rue Egide Van Ochem B 1180 Bruxelles
Estonian: LU- Luksemburg Therabel Pharma 110 Rue Egide Van Ochem B 1180 Bruxelles
English: - The Committee considered the Referral made under Article 6(12) of Commission Regulation (EC) No 1084/2003, for Octegra and associated names (See Annex 1).
Estonian: - komitee vaatas läbi komisjoni määruse (EÜ) nr 1084/2003 artikli 6 lõike 12 kohaselt esitatud esildise Octegra ja sellega seotud nimetuste kohta (vt I lisa);
English: Bayer HealthCare AG 51368 Leverkusen Germany
Estonian: Bayer Healthcare AG 51368 Leverkusen Saksamaa
English: Bayer Healthcare AG 51368 Leverkusen Germany
Estonian: Bayer HealthCare AG 51368 Leverkusen Saksamaa
English: This procedure is a referral following a Mutual Recognition Procedure concerning the above variation application which was submitted for Octegra film-coated tablets to Germany as Reference Member State (RMS) and the Concerned Member States (CMS) AT, BE, EL, ES, FR, IT, LU, NL and PT on 5 December 2006.
Estonian: Käesoleva menetluse aluseks olev esildis esitati vastastikuse tunnustamise menetluse tulemusena, milles käsitleti 5. detsembril 2006 Saksamaale kui viiteliikmesriigile ja asjaomastele liikmesriikidele (AT, BE, EL, ES, FR, IT, LU, NL ja PT) esitatud taotlust Octegra õhukese polümeerikattega tablettide eespool mainitud müügiloas muudatuse tegemiseks.
English: Octegra film-coated tablets contain 400 mg moxifloxacin as hydrochloride.
Estonian: Octegra õhukese polümeerikattega tabletid sisaldavad 400 mg moksifloksatsiini vesinikkloriidina.
English: Objections and concerns over the efficacy and safety of Octegra in the proposed indication were raised during the Mutual Recognition variation procedure.
Estonian: Muudatuse tegemiseks läbiviidud vastastikuse tunnustamise menetluse käigus tõstatati seoses Octegra ohutuse ja efektiivsusega kavandatud näidustuse puhul teatavad vastuväited ja probleemid.
English: The MRP variation application DE/H/156/01/II/34 concerned an extension of the indication to include the treatment of mild to moderate pelvic inflammatory disease (PID), i.e. infections of upper genital tract, including salpingitis and endometritis.
Estonian: Vastastikuse tunnustamise menetluseks esitatud muudatuse taotluses DE/H/156/01/II/34 soovitati laiendada näidustust kerge kuni mõõduka raskusastmega väikevaagna põletikule, s.t genitaaltrakti ülemise osa nakkustele, kaasa arvatud salpingiit ja endometriit.
English: - The Committee considered that robust data is available showing the efficacy of Octegra in the indication “Treatment of mild to moderate pelvic inflammatory disease (PID), i.e. infections of upper genital tract, including salpingitis and endometritis” , however due to emerging resistance of N. gonorrhoeae, moxifloxacin should not be used in empirical monotherapy, unless moxifloxacinresistant N. gonorrhoeae can be excluded.
Estonian: - komitee leidis, et on kättesaadavad usaldusväärsed andmed, mis näitavad Octegra efektiivsust kasutamisel näidustuse “kerge või mõõduka väikevaagna põletiku, s.t genitaaltrakti ülemise osa nakkuste, sh salpingiidi ja endometriidi ravi" puhul, kuid N. gonorrhoeae resistentsuse suurenemise tõttu võib moksifloksatsiini empiirilise monoteraapiana kasutada vaid sel juhul, kui N. gonorrhoeae resistentsuse moksifloksatsiini suhtes võib välistada;
English: - The Committee, in view of the presented data on efficacy and safety, considered that the Benefit / Risk balance for Octegra and associated names in the “ The treatment of mild to moderate pelvic inflammatory disease (PID), i.e. infections of upper genital tract, including salpingitis and endometritis” with the restrictions concerning empirical monotherapy was favourable; - The CHMP, as a consequence, recommended the amendment of the Summary of Product Characteristics sections 4.1, 4.2, 4.3, 4.4, 5.1 and 5.2 and Package Leaflet relevant sections as set out in Annex III for Octegra and associated names (see Annex I).
Estonian: - seetõttu soovitas inimravimikomitee teha ravimi omaduste kokkuvõtte lõikudes 4.1, 4.2, 4.3, 4.4, 5.1 ja 5.2 ja pakendi infolehe asjakohastes lõikudes muudatused, mis on esitatud III lisas Octegra ja sellega seotud nimetuste kohta (vt I lisa).
English: 400 mg
Estonian: 4 mg/l
English: Cattle, cats, dogs
Estonian: Veised, kassid, koerad
English: Intramuscular or intravenous
Estonian: Intramuskulaarne või intravenoosne
English: However, the efficacy assessment does not fall within the scope of this referral procedure.
Estonian: Efektiivsuse hindamine ei kuulu käesoleva esildismenetluse käsitlusalasse.
English: Germany1 CP-Pharma Handelsgesellschaft mbH Ostlandring 13
Estonian: Saksamaa1 CP-Pharma Handelsgesellschaft mbH
English: These veterinary medicinal products are also authorised for use in dogs and cats, but considering the scope of the referral, these target species were not assessed during this procedure.
Estonian: Need veterinaarravimid on heaks kiidetud kasutamiseks ka koertel ja kassidel, kuid esildismenetluse käsitlusala tõttu neid sihtliike käesolevas menetluses ei hinnatud.
English: Zoetis France 23-25 Avenue du Dr Lannelongue 75014 Paris France
Estonian: Prantsusmaa Zoetis France 23-25 Avenue du Dr Lannelongue
English: List of the names, pharmaceutical forms, strengths of the veterinary medicinal products, animal species, routes of administration, applicant/marketing authorisation holder in the Member States
Estonian: Veterinaarravimite nimetuste, ravimvormide, tugevuste, loomaliikide, manustamisviiside ja müügiloa taotlejate/hoidjate loetelu liikmesriikides
English: Therefore, on 2 May 2016, Germany initiated a procedure under Article 35 of Directive 2001/82/EC, for veterinary medicinal products containing methylprednisolone hydrogen succinate presented as solutions for injection for intramuscular use in cattle.
Estonian: Sel põhjusel algatas Saksamaa 2. mail 2016 direktiivi 2001/82/EÜ artikli 35 kohase menetluse, mis käsitleb metüülprednisoloon-vesiniksuktsinaati sisaldavaid veistele intramuskulaarse süstelahusena manustatavaid veterinaarravimeid.
English: In addition, the pharmacological ADI was exceeded up to 262 fold at day 7 and up to 2.8 fold at day 14.
Estonian: Peale selle ületas kogus farmakoloogilist aktsepteeritavat ööpäevast kogust 7. päeval kuni 262 korda ja 14. päeval kuni 2,8 korda.
English: However, the first time point all data were below the MRL was day 21.
Estonian: Esimene hetk, mil kõik näitajad olid alla ravimijääkide piirnormi, oli 21. päev.
English: • After administration of 400 µg/kg bw for 5 consecutive days, residues in injection site muscle ranged from below LOQ (10 µg/kg) to 8393 µg/kg at day 7 after injection and at day 14 from below LOQ to 90 µg/kg.
Estonian: • Pärast ravimi manustamist annuses 400 µg/kg 5 järjestikusel päeval oli jääkide kogus süstekoha lihases vahemikus alla määramispiiri (10 µg/kg) kuni 8393 µg/kg 7. päeval pärast süstet ning 14. päeval vahemikus alla määramispiiri kuni 90 µg/kg.
English: The residue depletion data do not allow a statistically based determination of a withdrawal period.
Estonian: Ravimijääkide kadumise andmed ei võimalda keeluaja statistikapõhist määramist.
English: Overall summary of the scientific evaluation of veterinary medicinal products containing methylprednisolone hydrogen succinate for use in target species cattle (see Annex I)
Estonian: Veistel kasutatavate metüülprednisoloon-vesiniksuktsinaati sisaldavate veterinaarravimite (vt I lisa) teadusliku hindamise üldkokkuvõte
English: Veterinary medicinal products containing methylprednisolone hydrogen succinate are used for treatment of inflammatory or allergic conditions and also for treatment and prevention of shock conditions.
Estonian: Metüülprednisoloon-vesiniksuktsinaati sisaldavaid veterinaarravimeid kasutatakse põletikuliste või allergiliste seisundite raviks ning ka šokiseisundite raviks ja ennetamiseks.
English: Animal species
Estonian: Loomaliigid Manustamisviis
English: Methylprednisolone, a 6α-methyl derivative of prednisolone, is a synthetic corticosteroid, which is used in veterinary medicine as a free alcohol, and as various esters.
Estonian: Prednisolooni 6α-metüleeritud derivaat metüülprednisoloon on sünteetiline kortikosteroid, mida kasutatakse veterinaarmeditsiinis vaba alkoholi ja mitmesuguste estritena.
English: The residue depletion data concerning methylprednisolone can be summarised as follows:
Estonian: Metüülprednisolooni jääkide kadumise andmed on kokkuvõttes järgmised.
English: 2 CVMP EPMAR for methylprednisolone (EMEA/MRL/798/01-FINAL)http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits__Report/2009/11/WC500015081.pdf alcohol) and two antibiotic substances (neomycin and benzylpenicillin).
Estonian: 2 CVMP EPMAR for methylprednisolone (EMEA/MRL/798/01-FINAL)http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits__Report/2009/11/WC500015081.pdf kombinatsiooni sisaldavat veterinaarravimit.
English: Methylprednisolone hydrogen succinate is an ester of the synthetic glucocorticoid methylprednisolone.
Estonian: Metüülprednisoloon-vesiniksuktsinaat on sünteetilise glükokortikoidi metüülprednisolooni ester.
English: Residues in muscle, liver, kidney and fat were already below LOQ (10 µg/kg) at the earliest slaughter time (day 7).
Estonian: Ravimijääkide kogus lihases, maksas, neerudes ja rasvkoes oli varaseimal tapmisajal (7. päeval) juba alla määramispiiri (10 µg/kg).
English: Twenty-one days after administration residues at injection sites were below the LOQ in all animals.
Estonian: 21 päeva pärast manustamist oli ravimijääkide kogus süstekohtades kõikidel loomadel alla määramispiiri.
English: Following a marketing authorisation application to the Federal Office of Consumer Protection and Food Safety of Germany, under Article 13(1) of Directive 2001/82/EC, i.e., a generic application, for the veterinary medicinal product Solupred 125 mg (applicant: CP-Pharma), it appeared that no productspecific residue data are available in support of the cattle meat and offal withdrawal periods of 6 days for the reference products Solu-Medrol 120 mg and Solu-Medrol 500 mg which are authorised in France for use in dogs, cats and cattle (marketing authorisation holder: Zoetis).
Estonian: Pärast müügiloa taotluse esitamist Saksamaa tarbijakaitse ja toiduohutuse föderaalametile direktiivi 2001/82/EÜ artikli 13 lõike 1 alusel (geneerilise ravimi taotlus) seoses veterinaarravimiga Solupred 125 mg (taotleja: CP-Pharma) selgus, et puuduvad tootespetsiifilised ravimijääkide andmed, mis toetaks veiseliha ja söödavate kudede 6-päevast keeluaega võrdlusravimi Solu-Medrol 120 mg ja Solu-Medrol 500 mg korral, millel on Prantsusmaal müügiluba kasutamiseks koertel, kassidel ja veistel (müügiloa hoidja: Zoetis).
English: Taking all the information together, it cannot be confirmed from the available data that the withdrawal period of 6 days for cattle (meat and offal) for the reference product Solu-Medrol is safe for the consumer.
Estonian: Kõige selle teabe alusel ei saa kättesaadavate andmete põhjal kinnitada, et võrdlusravimi Solu-Medrol jaoks kehtestatud 6-päevane keeluaeg veiste (liha ja söödavad koed) korral on tarbijatele ohutu.
English: This conclusion applies to the administration of the products via the intramuscular route or the intravenous route.
Estonian: See järeldus kehtib ravimite intramuskulaarse või intravenoosse manustamise korral.
English: At the injection site, the MRL for muscle was exceeded more than 800 fold at day 7 and still 9 fold at day 14.
Estonian: Süstekoha lihases oli kogus 7. päeval üle 800 korra suurem kui ravimijääkide piirnorm ja 14. päeval veel 9 korda suurem.
English: No information has been found in open databases (e.g. PubMed, Scopus, VetMed Resource, Web of Science) regarding pharmacokinetic and residue data of methylprednisolone hydrogen succinate in edible tissues and at the injection site of cattle.
Estonian: Avalikest andmebaasidest (nt PubMed, Scopus, VetMed Resource, Web of Science) ei ole leitud andmeid metüülprednisoloon-vesiniksuktsinaadi farmakokineetiliste omaduste ja jääkide kadumise kohta veiste söödavatest kudedest ja süstekohast.
English: The only residue depletion study for methylprednisolone after intramuscular injection in cattle is cited in the CVMP EPMAR for methylprednisolone (EMEA/MRL/798/01-FINAL).
Estonian: Ainsale uuringule, mis käsitles ravimijääkide kadumist pärast metüülprednisolooni intramuskulaarset süstimist veistele, on viidatud veterinaarravimite komitee Euroopa avalikus ravimijääkide piirnormide hindamise aruandes metüülprednisolooni kohta (EMEA/MRL/798/01-FINAL).